The medication's long half-life of approximately one week allows for once-weekly dosing and sustained action between injections
Our journey began with a shared vision to empower individuals toward healthier lifestyles, offering a user-friendly and supportive space for your transformation
Silva to customize your clinical path
It points to the FDA continuing to approve new GLP-1 formulations and combination therapies, to oral, weekly injectable and combination peptide platforms broadening the options, and to compounding pharmacy networks adding access pathways under 503A regulation
"We made the decision not to prescribe GLP-1 medications early on because we believe that we are best positioned to serve as the behavior-change companion that health plans, PBMs, and large self-insured employers look to for GLP-1 companion care support for users throughout their journey," Wei-Li Shao, president of Omada Health told Fierce Healthcare